CN101317846A - 一种用于戒毒、镇痛的河豚毒素制剂 - Google Patents
一种用于戒毒、镇痛的河豚毒素制剂 Download PDFInfo
- Publication number
- CN101317846A CN101317846A CNA200810127045XA CN200810127045A CN101317846A CN 101317846 A CN101317846 A CN 101317846A CN A200810127045X A CNA200810127045X A CN A200810127045XA CN 200810127045 A CN200810127045 A CN 200810127045A CN 101317846 A CN101317846 A CN 101317846A
- Authority
- CN
- China
- Prior art keywords
- preparation
- fugu ocellatus
- tetrodotoxin
- ocellatus toxin
- analgesic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 53
- CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 title claims abstract description 40
- CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 title claims abstract description 39
- 229950010357 tetrodotoxin Drugs 0.000 title claims abstract description 39
- 229940079593 drug Drugs 0.000 title claims abstract description 36
- 239000000203 mixture Substances 0.000 title claims description 101
- 238000009472 formulation Methods 0.000 title claims description 92
- 229940083863 pain-ease Drugs 0.000 title 1
- 239000003053 toxin Substances 0.000 claims abstract description 134
- 238000002360 preparation method Methods 0.000 claims abstract description 92
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 49
- 238000000034 method Methods 0.000 claims abstract description 24
- 239000006184 cosolvent Substances 0.000 claims abstract description 19
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 15
- 150000001413 amino acids Chemical class 0.000 claims abstract description 9
- 241000054452 Takifugu ocellatus Species 0.000 claims description 142
- 231100000765 toxin Toxicity 0.000 claims description 133
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 123
- 239000000706 filtrate Substances 0.000 claims description 56
- 239000000843 powder Substances 0.000 claims description 50
- 239000000243 solution Substances 0.000 claims description 46
- 230000000202 analgesic effect Effects 0.000 claims description 37
- 238000001914 filtration Methods 0.000 claims description 37
- 238000004108 freeze drying Methods 0.000 claims description 34
- 239000008103 glucose Substances 0.000 claims description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
- 239000008215 water for injection Substances 0.000 claims description 25
- 239000003480 eluent Substances 0.000 claims description 22
- 238000002347 injection Methods 0.000 claims description 22
- 239000007924 injection Substances 0.000 claims description 22
- 238000001035 drying Methods 0.000 claims description 19
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 16
- 238000005406 washing Methods 0.000 claims description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- 238000007670 refining Methods 0.000 claims description 14
- 239000002435 venom Substances 0.000 claims description 13
- 231100000611 venom Toxicity 0.000 claims description 13
- 210000001048 venom Anatomy 0.000 claims description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 12
- 230000001476 alcoholic effect Effects 0.000 claims description 12
- 229920002307 Dextran Polymers 0.000 claims description 10
- 235000001014 amino acid Nutrition 0.000 claims description 10
- 229940024606 amino acid Drugs 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- 229910021529 ammonia Inorganic materials 0.000 claims description 8
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 7
- 235000013922 glutamic acid Nutrition 0.000 claims description 7
- 239000004220 glutamic acid Substances 0.000 claims description 7
- 238000004062 sedimentation Methods 0.000 claims description 7
- 239000004475 Arginine Substances 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 6
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 5
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 claims description 5
- 235000003704 aspartic acid Nutrition 0.000 claims description 5
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 5
- 239000003729 cation exchange resin Substances 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 5
- 230000006837 decompression Effects 0.000 claims description 5
- 239000000796 flavoring agent Substances 0.000 claims description 5
- 235000019634 flavors Nutrition 0.000 claims description 5
- 210000004185 liver Anatomy 0.000 claims description 5
- 210000001672 ovary Anatomy 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 claims description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- 238000007654 immersion Methods 0.000 claims description 2
- 229960003104 ornithine Drugs 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- 230000036592 analgesia Effects 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 10
- 238000003860 storage Methods 0.000 abstract description 8
- 239000007788 liquid Substances 0.000 abstract description 4
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 238000009938 salting Methods 0.000 abstract 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 50
- 238000012360 testing method Methods 0.000 description 40
- 241000699670 Mus sp. Species 0.000 description 28
- 229960005181 morphine Drugs 0.000 description 25
- 238000010438 heat treatment Methods 0.000 description 22
- 238000000108 ultra-filtration Methods 0.000 description 21
- 239000002904 solvent Substances 0.000 description 18
- 239000000047 product Substances 0.000 description 16
- 230000037396 body weight Effects 0.000 description 14
- 238000012856 packing Methods 0.000 description 14
- 238000010254 subcutaneous injection Methods 0.000 description 14
- 239000007929 subcutaneous injection Substances 0.000 description 14
- 208000002193 Pain Diseases 0.000 description 12
- 229960005195 morphine hydrochloride Drugs 0.000 description 11
- XELXKCKNPPSFNN-BJWPBXOKSA-N morphine hydrochloride trihydrate Chemical compound O.O.O.Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O XELXKCKNPPSFNN-BJWPBXOKSA-N 0.000 description 11
- RGPDIGOSVORSAK-STHHAXOLSA-N naloxone hydrochloride Chemical compound Cl.O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C RGPDIGOSVORSAK-STHHAXOLSA-N 0.000 description 11
- 230000036407 pain Effects 0.000 description 11
- 238000003825 pressing Methods 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 206010013754 Drug withdrawal syndrome Diseases 0.000 description 9
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 230000001954 sterilising effect Effects 0.000 description 9
- 238000004659 sterilization and disinfection Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 229960004127 naloxone Drugs 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 6
- -1 hydrochlorate Chemical compound 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 235000013372 meat Nutrition 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 208000031648 Body Weight Changes Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 238000000540 analysis of variance Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000004579 body weight change Effects 0.000 description 5
- 239000003651 drinking water Substances 0.000 description 5
- 235000020188 drinking water Nutrition 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 230000004580 weight loss Effects 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- 238000012449 Kunming mouse Methods 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000001784 detoxification Methods 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 210000002345 respiratory system Anatomy 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- 206010012335 Dependence Diseases 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 238000000151 deposition Methods 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 230000003292 diminished effect Effects 0.000 description 3
- 206010013663 drug dependence Diseases 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229960005250 naloxone hydrochloride Drugs 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 208000011117 substance-related disease Diseases 0.000 description 3
- 230000001550 time effect Effects 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical group CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 210000001217 buttock Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229960002433 cysteine Drugs 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004118 muscle contraction Effects 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000004130 Blepharoptosis Diseases 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010001394 Disaccharidases Proteins 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 208000008630 Sialorrhea Diseases 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241001441726 Tetraodontiformes Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010048232 Yawning Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 229940048432 naloxone 2 mg Drugs 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200810127045XA CN101317846B (zh) | 2008-05-28 | 2008-06-18 | 一种用于戒毒、镇痛的河豚毒素制剂 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200810111343.X | 2008-05-28 | ||
CN200810111343 | 2008-05-28 | ||
CN200810127045XA CN101317846B (zh) | 2008-05-28 | 2008-06-18 | 一种用于戒毒、镇痛的河豚毒素制剂 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010102279942A Division CN101891751B (zh) | 2008-06-18 | 2008-06-18 | 一种河豚毒素的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101317846A true CN101317846A (zh) | 2008-12-10 |
CN101317846B CN101317846B (zh) | 2010-11-10 |
Family
ID=40178286
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200810127045XA Expired - Fee Related CN101317846B (zh) | 2008-05-28 | 2008-06-18 | 一种用于戒毒、镇痛的河豚毒素制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101317846B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107176984A (zh) * | 2017-06-08 | 2017-09-19 | 赵恩成 | 一种蝎肽及其制备方法 |
CN107880054A (zh) * | 2017-10-09 | 2018-04-06 | 浙江省海洋水产研究所 | 一种制备高纯河豚毒素的方法 |
CN113321661A (zh) * | 2021-05-04 | 2021-08-31 | 中洋生物科技(上海)股份有限公司 | 一种高效的从河豚内脏提取和分离制备高纯度河豚毒素的方法 |
WO2022221963A1 (en) * | 2021-04-23 | 2022-10-27 | Wex Pharmaceuticals Inc. | Tetrodotoxin liquid formulations |
WO2024007068A1 (en) * | 2022-07-06 | 2024-01-11 | Wex Pharmaceuticals Inc. | Process for the extraction and purification of tetrodotoxin |
-
2008
- 2008-06-18 CN CN200810127045XA patent/CN101317846B/zh not_active Expired - Fee Related
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107176984A (zh) * | 2017-06-08 | 2017-09-19 | 赵恩成 | 一种蝎肽及其制备方法 |
CN107880054A (zh) * | 2017-10-09 | 2018-04-06 | 浙江省海洋水产研究所 | 一种制备高纯河豚毒素的方法 |
WO2022221963A1 (en) * | 2021-04-23 | 2022-10-27 | Wex Pharmaceuticals Inc. | Tetrodotoxin liquid formulations |
CN113321661A (zh) * | 2021-05-04 | 2021-08-31 | 中洋生物科技(上海)股份有限公司 | 一种高效的从河豚内脏提取和分离制备高纯度河豚毒素的方法 |
CN113321661B (zh) * | 2021-05-04 | 2022-04-12 | 中洋生物科技(上海)股份有限公司 | 一种高效的从河豚内脏提取和分离制备高纯度河豚毒素的方法 |
WO2022233298A1 (zh) * | 2021-05-04 | 2022-11-10 | 中洋生物科技(上海)股份有限公司 | 一种高效的从河豚内脏提取和分离制备高纯度河豚毒素的方法 |
JP2023532153A (ja) * | 2021-05-04 | 2023-07-26 | 中洋生物科技(上海)股▲ふん▼有限公司 | フグ内臓由来の高純度テトロドトキシンの効率的な抽出、分離、調製の方法 |
JP7554357B2 (ja) | 2021-05-04 | 2024-09-19 | 中洋生物科技(上海)股▲ふん▼有限公司 | フグ内臓由来の高純度テトロドトキシンの効率的な抽出、分離、調製の方法 |
WO2024007068A1 (en) * | 2022-07-06 | 2024-01-11 | Wex Pharmaceuticals Inc. | Process for the extraction and purification of tetrodotoxin |
Also Published As
Publication number | Publication date |
---|---|
CN101317846B (zh) | 2010-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240041984A1 (en) | Methods for producing stable therapeutic formulations in aprotic polar solvents | |
CN103442695A (zh) | 肠胃外注射用肽药物的稳定制剂 | |
CN101317846B (zh) | 一种用于戒毒、镇痛的河豚毒素制剂 | |
GB2513060A (en) | Microparticle buprenorphine suspension | |
BR112020019192A2 (pt) | Composição farmacêutica que compreende ácido deoxicólico | |
EP2589382A1 (en) | Pharmaceutical composition comprising levocarnitine and dobesilate | |
CN111848512B (zh) | 使用高纯度盐酸罂粟碱制备粉针剂药物组合物 | |
CN102058593A (zh) | 艾普拉唑钠的组合药物及其制备工艺 | |
CN101891751B (zh) | 一种河豚毒素的制备方法 | |
JP2007507422A (ja) | テトロドトキシンの安定な凍結乾燥医薬製剤 | |
CN105078909B (zh) | 一种注射用苯磺顺阿曲库铵冷冻干燥组合物及其制备方法 | |
WO2011006653A1 (en) | An agent for restoring lost memory on the basis of n,n'-substituted 3,7-diazabicyclo[3.3.1] nonanes | |
RU2005135428A (ru) | Поглощение макромолекул | |
JP6950966B2 (ja) | スガマデクス又はその薬理学的に許容される塩含有液剤及びその製造方法 | |
EP3442557B1 (en) | A drug formulation for use in the effective control of acute and/or chronic pain | |
CN111789818B (zh) | 注射用盐酸罂粟碱药物组合物及制备方法 | |
CN111796043B (zh) | 注射用盐酸罂粟碱粉针剂及其质量检测方法 | |
CN114028537A (zh) | 一种含有svhrsp蝎毒肽的药物组合物及其制备方法 | |
CN100396289C (zh) | 灯盏花乙素注射制剂及其制备方法 | |
CN101703466A (zh) | 冰片注射剂及其制剂方法 | |
US11590205B2 (en) | Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents | |
CN1457780A (zh) | 植物来源总生物碱组合物及其药物制剂 | |
CN103877010A (zh) | 一种罗米地辛溶液的制备方法 | |
CN106937944A (zh) | 一种注射用甲硝唑冻干粉针制剂及其制备方法 | |
US20190336572A1 (en) | Composition and method for oral delivery of stable formulations of cobra venom |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20090320 Address after: Room 6, building 632, D District, 137 Lanxi Road, Shanghai, Putuo District: 200062 Applicant after: Shanghai Yinian Biotech Co., Ltd. Address before: Beijing City, Haidian District North Fourth Ring Road No. 4 Building 1207 room Jianxiang Park Post encoding: 100083 Applicant before: Wang Kaiye |
|
ASS | Succession or assignment of patent right |
Owner name: SHANGHAI YINIAN BIOLOGY SCIENCE CO., LTD. Free format text: FORMER OWNER: WANG KAIYE Effective date: 20090320 |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101110 Termination date: 20120618 |